Loading asset research
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNasdaq · USD · StocksQuote as of · Exchange session not verified$22.80
+4.30%
Today
NAMS
Loading 1D prices…
Market cap
$2.7B
Volume
1.6M
52w high
$42.2152w low
$21.23Company profile
NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Naarden, Netherlands, United States
Employees
100
Fiscal year end
1231
CIK
1936258
Session & valuation
Open$22.11
Previous close$21.86
Day high$23.00
Day low$21.23
30-day avg. volume1.3M
Outstanding shares119.5M
Diluted EPS-$1.72
Latest annual period
P/E (trailing)-13.26
P/E (forward)-14.56
Price / book4.25
Beta0.09
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PHVSPharvaris N.V. Ordinary Shares | $2.7B | — | — | -$2.97 | +1.36% | Buy |
| IRONDisc Medicine Inc. Common Stock | $2.7B | $0.00 | — | -$6.01 | -5.62% | Buy |
| ZLABZai Lab Limited American Depositary Shares | $2.7B | $457.2M | -38.39% | -$0.16 | -0.17% | Buy |
| ATAIAtaiBeckley Inc. Common Stock | $2.7B | $4.1M | -16142.02% | -$2.91 | 0.00% | Hold |
| NRIXNurix Therapeutics Inc. Common stock | $2.6B | $84M | -314.90% | -$3.05 | -2.71% | Buy |